Soleno Therapeutics (NASDAQ:SLNO) is one of the 17 biotechnology stocks with more than 50% upside. On January 20, the price target on Soleno Therapeutics (NASDAQ:SLNO) was increased from $110 to $120 by Ram Selvaraju from H.C. Wainwright. He also reaffirmed his Buy rating on the stock, which, as per his forecasts, offers an upside potential of almost 211%. The analyst based his rating on the company’s impressive sales figures, which continue to beat estimates. Likoper/Shutterstock.com On January 20, We ...

Soleno indicated it is not currently planning to provide full-year guidance , citing the need for the business to mature further and for the company to better understand “ebbs and flows” in launch dynamics, though management said guidance remains “on the table” once it is comfortable.While the company declined to discuss the current quarter’s performance, executives reiterated a longer-term view of launch progress. CEO Anish Bhatnagar said investors should think about roughly 10% of total addressable market ...

Summary of Soleno Therapeutics Conference Call Company Overview - **Company**: Soleno Therapeutics (NasdaqCM:SLNO) - **Industry**: Rare Disease Biopharmaceuticals - **Product**: First approved treatment for Prader-Willi syndrome (PWS), a genetic disorder characterized by hyperphagia, with no prior treatments available [5][38] Key Points and Arguments Market Position and Growth Expectations - Soleno currently holds approximately **10%** of the total addressable market (TAM) with a target of reaching another **10%** over the next **9-12 months**, equating to about **250 Start Forms** per quarter [7][12] - The company anticipates moving from Start Forms to traditional metrics of revenue and active patients after the first quarter of 2026 [10] - The expectation is that the holiday variability seen in the previous quarter will not recur, as there are no major holidays in the current quarter [8] Patient Flow and Revenue Generation - The process for Start Forms involves a **30-45 day** assessment period through their specialty pharmacy partner, Panther, with a small percentage of forms being canceled [14] - The discontinuation rate for patients is expected to stabilize between **15%-20%**, which is considered healthy for a rare disease context [15][24] - Active patient revenue is driven by a combination of paid and free patients, with adherence impacting overall revenue [17][18] Financial Guidance and Revenue Trends - Soleno is not providing full-year guidance for 2026 as the business is still maturing [11] - The company expects a **seasonal increase** in Gross to Net discounts in the first quarter due to resets in copay and potential changes in patient coverage [20][21] - The overall discontinuation rate as of the fourth quarter was approximately **15%**, with **12%** being adverse event-related [23] Clinical and Market Insights - Adverse events (AEs) reported in the real-world setting are consistent with those observed in clinical trials, primarily non-serious [26] - Most patients are titrating to their prescribed doses, with a few exceptions due to comorbidities [27][28] - The average wholesale acquisition cost (WAC) is currently in the **$500,000s**, with expectations of gradual increases over the next few years [31][32] Market Expansion and Reimbursement - Soleno has coverage for approximately **185 million lives**, with expectations for this number to increase as reimbursement policies improve [42] - The company is experiencing a favorable reimbursement environment, with no significant issues reported regarding prior authorizations [44] - There is a growing number of prescribers, with over **600** currently, which exceeds initial expectations [41] International Opportunities - The company is preparing for potential CHMP approval in Europe, with an estimated patient population of **9,500** in the EU and UK [47] - Soleno is considering launching the product independently in Europe while also exploring partnership opportunities [49] Capital Deployment Strategy - Soleno plans to focus on sustaining the success of its launch and exploring other indications, while also considering inorganic growth opportunities [50] Additional Important Insights - The company acknowledges the challenges of educating prescribers unfamiliar with PWS and the drug, which is crucial for improving treatment outcomes [45] - There is a noted social aspect influencing patient adherence and return to treatment, as positive patient experiences are shared within the community [34] This summary encapsulates the key insights and strategic directions discussed during the conference call, highlighting Soleno Therapeutics' current market position, growth expectations, and operational strategies in the rare disease sector.

REDWOOD CITY, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced that it will report its fourth quarter and full-year 2025 financial results, as well as operational highlights, after the close of the U.S. financial markets on Wednesday, February 25, 2026. The Company will host a conference call and webcast at 4:30 PM Eastern Time to discuss the results and ...

Core Viewpoint - Soleno Therapeutics, Inc. (SLNO) has experienced significant selling pressure, resulting in an 18.3% decline in stock price over the past four weeks, but analysts anticipate improved earnings in the near future [1] Group 1: Technical Analysis - The Relative Strength Index (RSI) is utilized to determine if SLNO is oversold, with a current reading of 28.79 indicating potential for a trend reversal [2][5] - RSI serves as a momentum oscillator that helps identify price movement changes, suggesting that SLNO may be undervalued due to excessive selling pressure [3] Group 2: Fundamental Analysis - Analysts have raised earnings estimates for SLNO by 7.8% over the last 30 days, indicating a positive trend that typically correlates with stock price appreciation [7] - SLNO holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks, further supporting the potential for a near-term turnaround [8]

Group 1 - Soleno Therapeutics, Inc. is participating in several investor conferences in February and March 2026, including the Guggenheim Emerging Outlook: Biotech Summit, Oppenheimer 36th Annual Healthcare Life Sciences Conference, and TD Cowen 46th Annual Health Care Conference [1] - The company’s first commercial product, VYKAT™ XR (diazoxide choline) extended-release tablets, was approved by the FDA on March 26, 2025, for the treatment of hyperphagia in individuals with Prader-Willi syndrome aged 4 years and older [2]

Core Viewpoint - Soleno Therapeutics, Inc. (NASDAQ:SLNO) is identified as a stock with significant upside potential, with multiple analysts maintaining bullish outlooks despite some mixed signals regarding its performance [1][2]. Group 1: Analyst Ratings and Price Targets - H.C. Wainwright raised the target price for SLNO from $110 to $120, indicating strong confidence in the stock's future performance [1]. - Wells Fargo analyst Derek Archila maintained a price target of $106, reflecting a positive sentiment towards the stock [1]. - Cantor Fitzgerald's Kristen Kluska reiterated a Buy rating with a price target of $123, further supporting the bullish outlook [1]. - Wolfe Research cut its price target from $75 to $60 but still maintains a Buy rating, suggesting a potential upside of 41.7% from current levels [2]. Group 2: Company Overview and Market Performance - Soleno Therapeutics operates as a clinical-stage biopharmaceutical company focused on developing novel therapeutics for rare diseases, founded in 1999 and based in Redwood City, California [3]. - The company's fourth-quarter sales of Vykat XR exceeded consensus expectations, although there are concerns regarding weaker new patient starts impacting stock performance [2]. - Wolfe Research noted that the current market valuation reflects a bear-case scenario for product uptake, while its base-case outlook anticipates a more moderate decline in new patient starts than currently priced in by the market [2].

Core Viewpoint - Soleno Therapeutics, Inc. (NASDAQ:SLNO) is identified as a promising investment opportunity with significant upside potential, supported by recent positive financial results and analyst upgrades [1][2][3]. Financial Performance - Soleno Therapeutics announced preliminary unaudited full-year 2025 net revenue for its VYKAT XR offering, exceeding estimates by $16.5 million to $18.5 million [2] - The anticipated preliminary fourth-quarter 2025 net revenue is projected to be between $90 million and $92 million, significantly higher than the analyst guidance of $73.8 million [2]. Analyst Ratings and Price Targets - H.C. Wainwright raised the price target for Soleno Therapeutics to $120 from $110, indicating an upside potential of 177% [1] - Wells Fargo also increased its price target to $114 from $106 and maintained an Overweight rating, citing the strong fourth-quarter revenue performance [3]. Company Overview - Soleno Therapeutics is a California-based clinical-stage biopharmaceutical company founded in 1999, specializing in novel therapeutics for serious illnesses, including Diazoxide Choline Extended-Release tablets [4].

Core Insights - Artificial intelligence (AI) is identified as the greatest investment opportunity of the current era, with a strong emphasis on the urgency to invest now [1][13] - The energy demands of AI technologies are highlighted, with data centers consuming as much energy as small cities, leading to concerns about power grid strain and rising electricity prices [2][3] Investment Opportunity - A specific company is presented as a unique investment opportunity, positioned to benefit from the increasing energy demands of AI without being a chipmaker or cloud platform [3][6] - This company owns critical energy infrastructure assets that are essential for supporting the anticipated surge in energy consumption from AI data centers [7][8] Market Position - The company is described as a "toll booth" operator in the AI energy boom, profiting from the export of American LNG and poised to benefit from onshoring trends due to tariffs [5][6] - It is noted that the company is debt-free and has significant cash reserves, equating to nearly one-third of its market capitalization, which positions it favorably compared to other energy firms [8][10] Growth Potential - The company holds a substantial equity stake in another AI-related venture, providing investors with indirect exposure to multiple growth engines in the AI sector [9][10] - The stock is characterized as undervalued, trading at less than seven times earnings, which presents a compelling investment opportunity given its ties to the growing AI and energy markets [10][11] Industry Trends - The article emphasizes the ongoing disruption caused by AI across traditional industries, suggesting that companies that adapt will thrive while those that do not will struggle [11][12] - The influx of talent into the AI sector is noted, ensuring continuous innovation and advancements, further solidifying AI's role as a critical investment area [12][14]

Core Viewpoint - The law firm Kirby McInerney LLP is investigating Soleno Therapeutics, Inc. for potential violations of federal securities laws or unlawful business practices related to its product Vykat XR [1]. Group 1: Company Performance and Events - On August 15, 2025, Scorpion Capital published a report labeling Soleno's Vykat XR as overpriced and potentially unsafe for children, leading to a share price decline of $5.73, or approximately 7.41%, from $77.36 to $71.64 [3]. - During a quarterly earnings call on November 4, 2025, Soleno disclosed that the discontinuation rate of Vykat XR due to adverse effects was around 8% at the end of Q3 2025. The CEO noted a disruption in the product's launch trajectory following the Scorpion Capital report, resulting in a further share price drop of $16.98, or approximately 26.59%, from $63.85 to $46.87 [4].